Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

January 2019 Monthly Report: Number of Outstanding Listed Securities: 46,832,012

Nash Pharmaceuticals Progression

The Company has a number of additional in vivo research studies in progress with its lead drug candidates in order to build on the data that was collected from the initial research studies conducted by Nash Pharmaceuticals.

Management was successful in completing an investigational brochure and a phase IIa study synopsis protocol for the disease areas of chronic kidney disease (CKD) inflammatory bowel disease (IBD) and non-alcoholic steatohepatitis (NASH). These documents have been submitted to a number of contract research organization’s (CRO’s) that have an expertise in global clinical trials in order to complete an efficacy study. The efficacy study will help the company confirm all relevant details of the planed phase IIa studies.

Management has also initiated discussion with a number of global and regional pharma companies in an effort to receive feedback on its current research programs and to explore possible partnering and or licensing discussions.

On December 3rd, 2018, the Company announced that in a recent in vivo animal study for Crohn’s disease (CD), NP-178, its lead compound for the treatment of ulcerative colitis (UC), performed equivalent to and in some measurements, better than 5-ASA, a current global standard of care treatment for IBD. A new potential treatment for CD could lead to an orphan drug designation, which could help expedite its availability to patients. There are a number of countries globally, that have an orphan drug program in place whereby companies that develop drugs for certain rare diseases enjoy enhanced collaboration with the regulatory authority, incentives, marketing exclusivity, and improved pricing and reimbursement.

https://webfiles.thecse.com/Breathtec_-_CSE_Form_7_-_Monthly_Progress_Report_for_December_2018_Completed.pdf?bR7PnA6rmz68khgp1ku0J4FudQTz.7hp

IMO, I view the report as very aggressive in moving towards legitimacy of Nash Pharmaceuticals (a wholly owned subsidiary of Breathtec Biomedical Inc.).

The Research Use Only - FAIMS device remains under wraps (off the radar screen).

GL2ALL,

/////AMG